Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
104.15
-1.26 (-1.20%)
At close: Nov 14, 2025, 4:00 PM EST
104.61
+0.46 (0.44%)
After-hours: Nov 14, 2025, 7:52 PM EST
Incyte Revenue
Incyte had revenue of $1.37B in the quarter ending September 30, 2025, with 20.05% growth. This brings the company's revenue in the last twelve months to $4.81B, up 18.09% year-over-year. In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth.
Revenue (ttm)
$4.81B
Revenue Growth
+18.09%
P/S Ratio
4.20
Revenue / Employee
$1,839,169
Employees
2,617
Market Cap
20.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
INCY News
- 2 hours ago - Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) - Business Wire
- 6 days ago - Incyte Corporation (INCY) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript - Seeking Alpha
- 10 days ago - Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema - Business Wire
- 12 days ago - Top Biotech Stocks Riding The Rally - Seeking Alpha
- 13 days ago - Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting - Business Wire
- 17 days ago - 4 Best Value And Growth Stocks (Yes, They Can Coexist) - Seeking Alpha
- 17 days ago - Incyte to Present at Upcoming Investor Conferences - Business Wire
- 17 days ago - Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina - GlobeNewsWire